Daniel G. Fuster

We need effective drugs to prevent stones !

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention - The Lancet thelancet.com/journals/lance… Congratulations to the study team for the conduct of this trial. Longterm adherence to dietary recommendations remains a major challenge…..

Obinutuzumab shows significant efficacy in active SLE.

Join this global initiative, CRESCENDO, which collects data on patients with crescentic lesions on their kidney biopsy. Reach out to one of the team members. 6 continents, over 100 centers have registered already! academic.oup.com/ckj/advance-ar… @AnnetteBruchfe1 and Vanja Ivkovic

🚀 STOP-PKD-News! Das zweite Prüfzentrum in Mainz ist nun offiziell freigegeben. Weitere folgen (DE, NL, ES, AT). Kann SGLT2-Inhibition das Fortschreiten von Zystennieren positiv beeinflussen? Infos und Kontakte: stop-pkd.de #STOPPKD #ADPKD @PKD_Int

I am glad to work together with leading experts in the field of rare kidney diseases! Together these diseases are common! Thank you @GlomCon

🧩 Many have wondered why the 1st-gen anti-miR-17 oligo RGLS4326 for #ADPKD didn’t advance, despite promising early clinical data. 💉At very high doses, it caused CNS toxicity in preclinical studies. Our @NatureComms paper explains why 🔗 nature.com/articles/s4146…

IgA Nephropathy with two global leaders @MarkusAtHome: An honor and pleasure to host @IgAN_JBarratt @jradnephro For our best of @NDTsocial webinar picked by @AKronbichler @hjanders_hans youtu.be/l0g9_lkW5_w?si… via @YouTube

@Tobias_B_Huber Thank you, dear Tobi — your friendship and leadership mean a great deal. No one advances alone; we are all part of a shared mission to understand and ultimately eliminate kidney disease. The future of nephrology is bright when science, collaboration, and vision come together.

Happy to see our review on "challenges" in ANCA-associated vasculitis published in @NatRevRheumatol! A special thanks to the Editorial Team and also @martacasalmoura for leading this initiative! #vasculitis @EUVAS19 @vasculitides

Congratulations Biff. Well deserved

Congrats to ⁦@samirparikhmd⁩ and team⁩ for a breakthrough paper in ⁦@ScienceMagazine⁩ showing that somatically acquired heteroplasmic mtDNA mutations are a cause of chronic kidney disease and are functionally reversible. ⁦⁦@ASNKidney⁩ ⁦@the_asci⁩ 👇👇

@AKronbichler @sara___helena @Tobias_B_Huber @MarcusSaemann Fantastic meeting. Congratulations Sara and Andreas - well done !!

The inaugural YNA meeting came to an end! @sara___helena must be commended for the visibility of #YNA!

YNA Symposium Day 1 was a success🎉🫘☺️ @YNAnephro

Congratulations to @milena_bond and the Firenze Team!

An exceptional case we diagnosed 2 years ago with an extrarenal "crescent" formation (paravertebral mass). In the supplement you will see a selection of other rare manifestations including rupture of the A colica dextra. kidney-international.org/article/S0085-…

Just out in Nature Reviews Nephrology. Kidney stone disease: risk factors, pathophysiology and management. nature.com/articles/s4158…

Incredible work - congratulations Sarah and team ! JCI - Genetic variants predisposing to an increased risk of kidney stone disease jci.org/articles/view/…

🎉Herzliche Gratulation! Daniel Fuster #inselgruppe hat mit Lia Bally, Beat Roth, Andreas Christe & Eva Segelov einen #IICT-Grant des @snf_ch erhalten für die EMPASTONE-Studie zur Prävention von #Nierensteinen mit Empagliflozin & Ernährungsberatung!👏 @MedFacultyUniBE @unibern